Encore Medical's IPO timeline remains highly uncertain, with traders assigning an 81% implied probability to no listing before June 2026. The medtech firm, which develops septal occlusion devices for cardiac defects, filed its S-1 in September 2025 seeking to raise $15 million at approximately $5 per share to fund ongoing FDA clinical trials for U.S. approval. Recent updates through April 2026 highlighted continued reliance on European sales and lengthy trial timelines estimated at two years, limiting near-term revenue visibility and keeping post-IPO market capitalization expectations tightly clustered in the $45–55 million range at just 13.7% combined probability. Macro conditions, including elevated interest rates and cautious sentiment toward early-stage healthcare IPOs, have further delayed pricing, with any resolution now dependent on FDA progress or broader equity market stabilization.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於2026年6月前不會IPO 81%
4,500 萬–5,000 萬 7%
5,500萬+ 4.0%
低於4,500萬 2.6%
$24,088 交易量
$24,088 交易量
2026-04-22
低於4,500萬
3%
4,500 萬–5,000 萬
7%
5,000 萬–5,500 萬
7%
5,500萬+
4%
2026年6月前不會IPO
81%
2026年6月前不會IPO 81%
4,500 萬–5,000 萬 7%
5,500萬+ 4.0%
低於4,500萬 2.6%
$24,088 交易量
$24,088 交易量
2026-04-22
低於4,500萬
$7,323 交易量
3%
4,500 萬–5,000 萬
$2,625 交易量
7%
5,000 萬–5,500 萬
$1,823 交易量
7%
5,500萬+
$3,121 交易量
4%
2026年6月前不會IPO
$9,195 交易量
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Encore Medical's IPO timeline remains highly uncertain, with traders assigning an 81% implied probability to no listing before June 2026. The medtech firm, which develops septal occlusion devices for cardiac defects, filed its S-1 in September 2025 seeking to raise $15 million at approximately $5 per share to fund ongoing FDA clinical trials for U.S. approval. Recent updates through April 2026 highlighted continued reliance on European sales and lengthy trial timelines estimated at two years, limiting near-term revenue visibility and keeping post-IPO market capitalization expectations tightly clustered in the $45–55 million range at just 13.7% combined probability. Macro conditions, including elevated interest rates and cautious sentiment toward early-stage healthcare IPOs, have further delayed pricing, with any resolution now dependent on FDA progress or broader equity market stabilization.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市場開放時間： Apr 3, 2026, 7:59 PM ET
交易量
$24,088結束日期
2026-04-22市場開放時間
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Encore Medical's IPO timeline remains highly uncertain, with traders assigning an 81% implied probability to no listing before June 2026. The medtech firm, which develops septal occlusion devices for cardiac defects, filed its S-1 in September 2025 seeking to raise $15 million at approximately $5 per share to fund ongoing FDA clinical trials for U.S. approval. Recent updates through April 2026 highlighted continued reliance on European sales and lengthy trial timelines estimated at two years, limiting near-term revenue visibility and keeping post-IPO market capitalization expectations tightly clustered in the $45–55 million range at just 13.7% combined probability. Macro conditions, including elevated interest rates and cautious sentiment toward early-stage healthcare IPOs, have further delayed pricing, with any resolution now dependent on FDA progress or broader equity market stabilization.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$24,088結束日期
2026-04-22市場開放時間
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Encore Medical's IPO timeline remains highly uncertain, with traders assigning an 81% implied probability to no listing before June 2026. The medtech firm, which develops septal occlusion devices for cardiac defects, filed its S-1 in September 2025 seeking to raise $15 million at approximately $5 per share to fund ongoing FDA clinical trials for U.S. approval. Recent updates through April 2026 highlighted continued reliance on European sales and lengthy trial timelines estimated at two years, limiting near-term revenue visibility and keeping post-IPO market capitalization expectations tightly clustered in the $45–55 million range at just 13.7% combined probability. Macro conditions, including elevated interest rates and cautious sentiment toward early-stage healthcare IPOs, have further delayed pricing, with any resolution now dependent on FDA progress or broader equity market stabilization.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions